Patents by Inventor Anna Wec

Anna Wec has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SARS-COV2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20260103506
    Abstract: The present disclosure is directed to antibodies and antigen binding fragments thereof, having improved binding specificity for coronaviruses, such as SARS-CoV-2, including neutralizing antibodies. Other embodiments contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.
    Type: Application
    Filed: July 1, 2025
    Publication date: April 16, 2026
    Inventors: Laura Walker, Anna Wec, Robert Allen, Brandyn West, Daniel Chupp
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 12209117
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: January 28, 2025
    Assignees: Biopharmaceutical, Inc., Albert Einstein College of Medicine, Adimab, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • Anti-yellow fever virus antibodies, and methods of their generation and use
    Patent number: 12110319
    Abstract: Antibodies and antigen-binding fragments thereof specific to the YFV E protein and with neutralizing potency against YFV are provided. These antibodies and antigen-binding fragments are useful in treating YFV.
    Type: Grant
    Filed: October 11, 2023
    Date of Patent: October 8, 2024
    Assignee: Mabloc, LLC
    Inventors: Anna Wec, Laura Walker
  • ANTI-YELLOW FEVER VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE
    Publication number: 20240218054
    Abstract: Antibodies and antigen-binding fragments thereof specific to the YFV E protein and with neutralizing potency against YFV are provided. These antibodies and antigen-binding fragments are useful in treating YFV.
    Type: Application
    Filed: October 11, 2023
    Publication date: July 4, 2024
    Inventors: Anna WEC, Laura WALKER
  • ANTI-YELLOW FEVER VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE
    Publication number: 20230203135
    Abstract: Antibodies and antigen-binding fragments thereof specific to the YFV E protein and with neutralizing potency against YFV are provided. These antibodies and antigen-binding fragments are useful in treating YFV.
    Type: Application
    Filed: October 11, 2022
    Publication date: June 29, 2023
    Inventors: Anna WEC, Laura WALKER
  • MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS
    Publication number: 20230044044
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Application
    Filed: July 1, 2022
    Publication date: February 9, 2023
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • Anti-yellow fever antibodies, and methods of their generation and use
    Patent number: 11479598
    Abstract: Antibodies and antigen-binding fragments thereof specific to the YFV E protein and with neutralizing potency against YFV are provided. These antibodies and antigen-binding fragments are useful in treating YFV.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: October 25, 2022
    Assignee: Mabloc, Inc.
    Inventors: Anna Wec, Laura Walker
  • Compounds specific to coronavirus S protein and uses thereof
    Patent number: 11414479
    Abstract: The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: August 16, 2022
    Assignee: Adagio Therapeutics, Inc.
    Inventors: Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 11407816
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: August 9, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF
    Publication number: 20220153815
    Abstract: The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated.
    Type: Application
    Filed: December 1, 2021
    Publication date: May 19, 2022
    Inventors: Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 11254732
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: February 22, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 11242378
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: February 8, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 11242379
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: February 8, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF
    Publication number: 20220010002
    Abstract: The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated.
    Type: Application
    Filed: August 18, 2021
    Publication date: January 13, 2022
    Inventors: Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
  • Compounds specific to coronavirus S protein and uses thereof
    Patent number: 11220536
    Abstract: The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: January 11, 2022
    Assignee: Adagio Therapeutics, Inc.
    Inventors: Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
  • COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF
    Publication number: 20210388067
    Abstract: The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated.
    Type: Application
    Filed: August 18, 2021
    Publication date: December 16, 2021
    Inventors: Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
  • Compounds specific to coronavirus S protein and uses thereof
    Patent number: 11192940
    Abstract: The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: December 7, 2021
    Assignee: Adagio Therapeutics, Inc.
    Inventors: Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
  • COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF
    Publication number: 20210324048
    Abstract: The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated.
    Type: Application
    Filed: April 9, 2021
    Publication date: October 21, 2021
    Inventors: Laura Walker, Laura Deveau, Jonathan Belk, Anna Wec, C. Garrett Rappazzo
  • ANTI-YELLOW FEVER ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE
    Publication number: 20210253675
    Abstract: Antibodies and antigen-binding fragments thereof specific to the YFV E protein and with neutralizing potency against YFV are provided. These antibodies and antigen-binding fragments are useful in treating YFV.
    Type: Application
    Filed: November 24, 2020
    Publication date: August 19, 2021
    Inventors: Anna WEC, Laura WALKER
  • Monoclonal antibodies and cocktails for treatment of ebola infections
    Patent number: 10836810
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: November 17, 2020
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker